CORE--CLINICAL AND RESEARCH

阿尔茨海默病（AD）的持续科学进展依赖于仔细评估患者和对照研究的可用性。临床研究发展核心的主要目标是通过提供记忆抱怨患者的基本诊断评估，促进遗传家族研究和Bryan ADRC的其他多学科努力。自1990年以来，我们在Bryan ADRC的神经系统疾病诊所（NDC）评估了5000多名新患者。我们计划专注于阿尔茨海默病和其他相关痴呆患者的持续高质量评估和治疗。我们还提出了继续发展针对非裔美国老年人和社区其他有色人种的多元文化临床服务的方法。确定家族遗传研究的阿尔茨海默病和其他晚发性痴呆。有超过75个家庭登记在该中心，其中有多生成的证据AD与尸检确认。我们计划继续开发和评估更多的信息家庭。与杜克大学人类遗传学中心（DCHG）合作，我们还打算使用新的兄弟姐妹对分析遗传方法研究AD患者未受影响的兄弟姐妹，以努力确定其他易感基因。继续在Bryan ADRC尸检项目中积极招募选定的患者和正常对照。目前，我们每年至少进行70例尸检，随访100多例AD患者和约200例非痴呆对照。在拨款期间，我们将继续目前的招生和临床评估实践，但我们也将重点关注在尸检项目的正常对照和痴呆协议中增加少数族裔的招生。促进老年痴呆症的临床研究。临床核心将继续作为Bryan ADRC研究的资源，并通过对AD风险增加的认知正常受试者的系统纵向研究，继续为外部研究确定AD的最早临床表型。

The continuing scientific progress in Alzheimer's disease (AD) relies on the availability of carefully evaluated patients and controls for study. The main goal of the Clinical Research Development Core is to facilitate genetic family studies and other multi-disciplinary efforts of the Bryan ADRC by providing the basic diagnostic assessment of patients with memory complaints. We have evaluated over 5000 new patients in the Neurological Disorders Clinic (NDC) of the Bryan ADRC since 1990. We plan to focus on continued high-quality evaluation and treatment of patients with AD and other related dementias. We also propose methods to continue to develop our multi-cultural clinical services to elderly African American and other people of color in the community. Identify families for genetic studies of AD and other late onset dementias. There are over 75 families enrolled in the Center in which there is multi- generated evidence of AD with autopsy confirmation. We plan to continue to develop and evaluate additional informative families. In conjunction with the Duke Center for Human Genetics (DCHG), we also intend to study unaffected siblings of AD patients using new genetic methods of sib-pair analysis, in an effort to identify other susceptibility genes. Continue the active enrollment of selected patients and normal controls in the Bryan ADRC autopsy program. Currently, we conduct at least 70 autopsies per year and follow over 100 patients with AD and approximately 200 non-demented controls. During the grant period we will continue our current enrollment and clinical evaluation practices but we will also make a strong focused effort on increasing minority enrollment in both the normal control and dementia protocols of the autopsy program. Facilitate clinical research studies of Alzheimer's disease. The Clinical Core will continue to be a resource to the research studies of the Bryan ADRC, and to external studies continues to be to define the earliest clinical phenotype of AD through systematic longitudinal study of cognitively normal subjects at enhanced risk of AD.